A Happy New Year 2023 from Thrombosis and Haemostasis

A happy new year to everyone from everyone at Thrombosis & Haemostasis, and with the new year, we see new challenges and some changes in the journal. As with our traditional new year's message, we aim to summarize our journey in the last year and look forward to 2023.[1] [2] [3] [4]

Another year has quickly passed, and as we emerge into more (three-dimensional) in-person meetings rather than the two-dimensional virtual meetings of various platforms, the journal also continues to grow.

Again, our editorial priorities are to ensure better manuscripts are published and faster turnaround of papers with more emphasis on priority ranking, leading to a higher rejection rate. We have also grown our open access journal, TH Open, which has had a steady growth of submissions and good quality publications that have been transferred from the main Thrombosis & Haemostasis journal.

Our acceptance rate is <25%, and our mean time to first editorial decision is 24 days. As editors and authors ourselves, we appreciate the need for speedy decision making, and our goal remains to get the time to first decision <21 days. Our submissions remain fairly steady (notwithstanding a COVID-related peak in 2020) keeping the editorial team busy.

Publikationsverlauf

Artikel online veröffentlicht:
10. Januar 2023

• References

• 1 Lip GYH, Rigby A, Weber C. A rollercoaster plunge into 2022. Thromb Haemost 2022; 122 (01) 1-4
• 2 Weber C, Rigby A, Lip GYH. Thrombosis and haemostasis 2021 editors' choice papers. Thromb Haemost 2022; 122 (01) 163-170
• 3 Lip GYH, Rigby A, Weber C. Looking back on 2020, looking forward to 2021. Thromb Haemost 2021; 121 (01) 1-3
• 4 Weber C, Rigby A, Lip GYH. Thrombosis and haemostasis 2020 editors' choice papers. Thromb Haemost 2021; 121 (01) 109-114
• 5 Zhai Z, Li C, Chen Y. et al; Prevention Treatment of VTE Associated with COVID-19 Infection Consensus Statement Group. Prevention and treatment of venous thromboembolism associated with coronavirus disease 2019 infection: a consensus statement before guidelines. Thromb Haemost 2020; 120 (06) 937-948
• 6 Bikdeli B, Madhavan MV, Gupta A. et al; Global COVID-19 Thrombosis Collaborative Group. Pharmacological agents targeting thromboinflammation in COVID-19: review and implications for future research. Thromb Haemost 2020; 120 (07) 1004-1024
• 7 Mycroft-West CJ, Su D, Pagani I. et al. Heparin inhibits cellular invasion by SARS-CoV-2: structural dependence of the interaction of the spike S1 receptor-binding domain with heparin. Thromb Haemost 2020; 120 (12) 1700-1715
• 8 Violi F, Pastori D, Cangemi R, Pignatelli P, Loffredo L. Hypercoagulation and antithrombotic treatment in coronavirus 2019: a new challenge. Thromb Haemost 2020; 120 (06) 949-956
• 9 Gerotziafas GT, Catalano M, Colgan MP. et al; Scientific Reviewer Committee. Guidance for the management of patients with vascular disease or cardiovascular risk factors and COVID-19: position paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. Thromb Haemost 2020; 120 (12) 1597-1628
• 10 Billett HH, Reyes-Gil M, Szymanski J. et al. Anticoagulation in COVID-19: effect of enoxaparin, heparin, and apixaban on mortality. Thromb Haemost 2020; 120 (12) 1691-1699
• 11 Potpara TS, Lip GYH, Blomstrom-Lundqvist C. et al. The 4S-AF Scheme (Stroke Risk; Symptoms; Severity of Burden; Substrate): a novel approach to in-depth characterization (rather than classification) of atrial fibrillation. Thromb Haemost 2021; 121 (03) 270-278
• 12 Kim HK, Tantry US, Smith Jr SC. et al. The East Asian Paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. Thromb Haemost 2021; 121 (04) 422-432
• 13 Eriksson O, Hultström M, Persson B. et al. Mannose-binding lectin is associated with thrombosis and coagulopathy in critically ill COVID-19 patients. Thromb Haemost 2020; 120 (12) 1720-1724
• 14 Giustozzi M, Agnelli G, Del Toro-Cervera J. et al. Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: a systematic review and meta-analysis. Thromb Haemost 2020; 120 (07) 1128-1136
• 15 von Hundelshausen P, Lorenz R, Siess W, Weber C. Vaccine-induced immune thrombotic thrombocytopenia (VITT): targeting pathomechanisms with bruton tyrosine kinase inhibitors. Thromb Haemost 2021; 121 (11) 1395-1399
• 16 Klug M, Lazareva O, Kirmes K. et al. Platelet surface protein expression and reactivity upon TRAP stimulation after BNT162b2 vaccination. Thromb Haemost 2022; 122 (10) 1706-1711
• 17 Romiti GF, Proietti M, Bonini N. et al; GLORIA-AF Investigators. Clinical complexity domains, anticoagulation, and outcomes in patients with atrial fibrillation: a report from the GLORIA-AF registry phase II and III. Thromb Haemost 2022; 122 (12) 2030-2041
• 18 Spyropoulos AC, Crawford JM, Chen YC. et al. Occurrence of thromboembolic events and mortality among hospitalized coronavirus 2019 patients: large observational cohort study of electronic health records. TH Open 2022; 6 (04) e408-e420
• 19 Kim SA, Lee JH, Lee JY. et al. Treatment and bleeding complications of cancer-associated venous thromboembolism: a Korean population-based study. Thromb Haemost 2022; 122 (12) 2011-2018
• 20 Gorog DA, Gue YX, Chao TF. et al. Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: executive summary of a European and Asia-Pacific expert consensus paper. Thromb Haemost 2022; 122 (10) 1625-1652
• 21 Chao TF, Joung B, Takahashi Y. et al. 2021 Focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: executive summary. Thromb Haemost 2022; 122 (01) 20-47